Top Institutional Investors

Deep Track Capital, LP — 13F Holdings & Portfolio

CIK 1856083 · latest 13F-HR filed 2026-08-14

Backtest portfolio

Deep Track Capital, LP manages $6.87B in 13F-reported U.S. long-equity assets across 67 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are GH (7.41%), IMVT (5.24%), GPCR (3.70%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 18 new positions and exited 14; 32 existing positions rose in reported value and 10 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$6.87B

Long-equity book

Holdings
67

Distinct positions

Period
2026-06-30

Filed 2026-08-14

Q/Q Activity
+18 / −14 / ↑32 / ↓10

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26
GH7.5% · +2%IMVT5.3% · -19%GPCR3.7% · +11%PCVX3.7% · 0%ALNY3.7% · newMANE3.6% · +300%TARS3.4% · +2%NUVL3.2% · +30%ALKS3.1% · +11%OCUL2.8% · 0%BMRN2.8% · +188%NRIX2.8% · +22%ORKA2.7% · -5%ALMS2.6% · -6%IONS2.6% · +13%CMPS2.5% · 0%VERA2.5% · -3%AXSM2.5% · -36%GMAB2.3% · +54%MLTX2.0% · +9%COAG1.9% · newTNGX1.9% · +53%DFTX1.9% · -8%GRAL1.8% · +6%BCAX1.8% · +1%MAZE1.6% · +7%CLDX1.6% · +129%LBRX1.6% · 0%MBX1.4% · -37%GHRS1.3% · newCOGT1.1% · +100%ATAI1.1% · +20%UTHR1.0% · newAVTX1.0% · newVRDN1.0% · +158%CYTK0.9% · -49%ALT0.9% · newPSNL0.8% · +33%ACRS0.7% · 0%CRMD0.7% · 0%WGS0.7% · newHROW0.6% · newCRVS0.5% · 0%SLDB0.5% · 0%BEAM0.5% · +22%DYN0.5% · -25%IMMX0.4% · newXFOR0.4% · -7%STTK0.4% · newMNKD0.4% · newIPSC0.3% · -0%GENB0.3% · newVSTM0.3% · 0%KURA0.3% · -25%ENTA0.3% · -26%NKTR0.3% · newOLMA0.3% · newKLRA0.2% · newKARD0.2% · newELVN0.2% · new

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 40.1%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 31, 2026.

Assets Under Management
$8.37B
Discretionary
$8.37B
Employees
19
Accounts
5
Address
200 GREENWICH AVENUE
3RD FLOOR
GREENWICH, CT 06830
Phone
(203) 409-0810
Website
Name Title / Status Ownership Type
DEEP TRACK CAPITAL GP, LLC ControlGENERAL PARTNER
since Sep 2020
Less than 5%Domestic Entity
KROIN DEVELOPMENT FUND, LLC ControlLIMITED PARTNER
since Oct 2020
25–50%Domestic Entity
KROIN, DAVID, ERIC ControlCHIEF INVESTMENT OFFICER
since Sep 2020
50–75%Individual
MESSAFI, NIR, SALMAN ControlCHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER
since Jan 2021
Less than 5%Individual
KROIN, DAVID, ERIC Control
Indirect owner via DEEP TRACK CAPITAL GP, LLC
MANAGING MEMBER
since Sep 2020
75% or moreIndividual
KROIN, MATTHEW, AARON Control
Indirect owner via THE DAVID E. KROIN 2020 FAMILY TRUST
TRUSTEE
since Oct 2020
General partner, trustee or managerIndividual
KROIN, MICHELLE, AIMEE Control
Indirect owner via THE DAVID E. KROIN 2020 FAMILY TRUST
TRUSTEE
since Oct 2020
General partner, trustee or managerIndividual
THE DAVID E. KROIN 2020 FAMILY TRUST Control
Indirect owner via KROIN DEVELOPMENT FUND, LLC
MANAGING MEMBER
since Oct 2020
75% or moreDomestic Entity
Ownership & leadership changes · 2 filings with changes since Feb 10, 2021

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 31, 2023 filing
  • ChangedMESSAFI, NIR, SALMAN · title CHIEF FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER → CHIEF OPERATING AND FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER
Feb 11, 2021 filing
  • AddedKROIN, MATTHEW, AARON · TRUSTEE · General partner, trustee or manager · indirect via THE DAVID E. KROIN 2020 FAMILY TRUST · control person
  • AddedKROIN, MICHELLE, AIMEE · TRUSTEE · General partner, trustee or manager · indirect via THE DAVID E. KROIN 2020 FAMILY TRUST · control person
Feb 10, 2021 filing (earliest on record)
  • ListedDEEP TRACK CAPITAL GP, LLC · GENERAL PARTNER · Less than 5% · control person
  • ListedKROIN DEVELOPMENT FUND, LLC · LIMITED PARTNER · 25–50% · control person
  • ListedKROIN, DAVID, ERIC · CHIEF INVESTMENT OFFICER · 50–75% · control person
  • ListedKROIN, DAVID, ERIC · MANAGING MEMBER · 75% or more · indirect via DEEP TRACK CAPITAL GP, LLC · control person
  • ListedMESSAFI, NIR, SALMAN · CHIEF FINANCIAL OFFICER / CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ListedTHE DAVID E. KROIN 2020 FAMILY TRUST · MANAGING MEMBER · 75% or more · indirect via KROIN DEVELOPMENT FUND, LLC · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Deep Track Capital, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 GUARDANT HEALTH INC GH 40131M109 $509.1M 7.41% 3,393,312 SH
2 IMMUNOVANT INC IMVT 45258J102 $359.9M 5.24% 9,341,151 SH
3 STRUCTURE THERAPEUTICS INC GPCR 86366E106 $254.4M 3.70% 4,740,072 SH
4 VAXCYTE INC PCVX 92243G108 $250.0M 3.64% 4,300,000 SH
5 ALNYLAM PHARMACEUTICALS INC ALNY 02043Q107 $248.3M 3.61% 825,000 SH
6 VERADERMICS INC MANE 922967104 $245.9M 3.58% 2,000,000 SH
7 TARSUS PHARMACEUTICALS INC TARS 87650L103 $230.8M 3.36% 3,666,768 SH
8 NUVALENT INC NUVL 670703107 $220.2M 3.21% 1,783,322 SH
9 ALKERMES PLC ALKS G01767105 $209.6M 3.05% 4,000,000 SH
10 OCULAR THERAPEUTIX INC OCUL 67576A100 $193.3M 2.81% 19,686,282 SH
11 BIOMARIN PHARMACEUTICAL INC BMRN 09061G101 $189.3M 2.75% 3,307,481 SH
12 NURIX THERAPEUTICS INC NRIX 67080M103 $187.7M 2.73% 7,736,455 SH
13 ORUKA THERAPEUTICS INC ORKA 687604108 $183.3M 2.67% 1,926,000 SH
14 ALUMIS INC ALMS 022307102 $178.6M 2.60% 6,348,558 SH
15 IONIS PHARMACEUTICALS INC IONS 462222100 $174.4M 2.54% 2,200,000 SH
16 COMPASS PATHWAYS PLC CMPS 20451W101 $172.1M 2.50% 12,161,496 SH
17 VERA THERAPEUTICS INC VERA 92337R101 $171.6M 2.50% 4,000,000 SH
18 AXSOME THERAPEUTICS INC. AXSM 05464T104 $171.3M 2.49% 700,000 SH
19 GENMAB A/S GMAB 372303206 $155.2M 2.26% 5,650,000 SH
20 MOONLAKE IMMUNOTHERAPEUTICS MLTX 61559X104 $136.3M 1.98% 6,999,025 SH
21 HEMAB THERAPEUTICS HLDGS INC COAG 423494103 $132.3M 1.93% 3,602,093 SH
22 TANGO THERAPEUTICS INC TNGX 87583X109 $131.3M 1.91% 4,200,000 SH
23 DEFINIUM THERAPEUTICS INC DFTX 24477V105 $129.4M 1.88% 2,750,000 SH
24 GRAIL INC GRAL 384747101 $125.3M 1.82% 1,834,944 SH
25 BICARA THERAPEUTICS INC BCAX 055477103 $121.7M 1.77% 4,100,000 SH
26 MAZE THERAPEUTICS INC MAZE 578784100 $111.4M 1.62% 3,732,569 SH
27 CELLDEX THERAPEUTICS INC NEW CLDX 15117B202 $109.4M 1.59% 2,939,151 SH
28 LB PHARMACEUTICALS INC LBRX 50180M108 $108.8M 1.58% 3,352,804 SH
29 MBX BIOSCIENCES INC MBX 55287L101 $95.6M 1.39% 1,732,569 SH
30 GH RESEARCH PLC GHRS G3855L106 $89.6M 1.30% 3,333,334 SH
31 GENMAB A/S Call GMAB 372303206 $82.4M 1.20% 3,000,000 SH
32 COGENT BIOSCIENCES INC COGT 19240Q201 $77.4M 1.13% 2,000,000 SH
33 ATAIBECKLEY INC ATAI 04650F101 $76.0M 1.11% 14,417,442 SH
34 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $67.0M 0.97% 123,616 SH
35 AVALO THERAPEUTICS INC AVTX 05338F306 $66.7M 0.97% 3,610,000 SH
36 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $66.0M 0.96% 3,592,740 SH
37 CYTOKINETICS INC CYTK 23282W605 $59.6M 0.87% 700,000 SH
38 ALTIMMUNE INC ALT 02155H200 $58.5M 0.85% 19,250,000 SH
39 PERSONALIS INC PSNL 71535D106 $53.6M 0.78% 4,000,000 SH
40 ACLARIS THERAPEUTICS INC ACRS 00461U105 $49.4M 0.72% 9,345,000 SH
41 CORMEDIX INC CRMD 21900C308 $49.3M 0.72% 6,274,076 SH
42 GENEDX HOLDINGS CORP WGS 81663L200 $48.1M 0.70% 700,000 SH
43 HARROW INC HROW 415858109 $41.2M 0.60% 969,000 SH
44 CORVUS PHARMACEUTICALS INC CRVS 221015100 $37.2M 0.54% 2,491,939 SH
45 SOLID BIOSCIENCES INC SLDB 83422E204 $35.6M 0.52% 3,565,062 SH
46 BEAM THERAPEUTICS INC BEAM 07373V105 $34.3M 0.50% 1,000,000 SH
47 DYNE THERAPEUTICS INC DYN 26818M108 $33.3M 0.48% 1,500,000 SH
48 IMMIX BIOPHARMA INC IMMX 45258H106 $28.6M 0.42% 2,775,000 SH
49 X4 PHARMACEUTICALS INC XFOR 98420X202 $27.5M 0.40% 5,878,757 SH
50 SHATTUCK LABS INC STTK 82024L103 $25.7M 0.37% 3,706,734 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-14 $6.87B 67 0001856083-26-000004
2026-03-31 2026-05-15 $6.12B 63 0001856083-26-000003
2025-12-31 2026-02-13 $5.61B 55 0001856083-26-000001
2025-09-30 2025-11-14 $3.58B 56 0001856083-25-000006
Filer Information
Address
200 GREENWICH AVENUE
3RD FLOOR
GREENWICH, CT 06830
Phone
(203) 409-0812
Filing Manager
Deep Track Capital, LP
GREENWICH, CT
Signatory
Nir Messafi
CCO/COO/CFO